missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ RU.521
Potent and selective inhibitor of cyclic GMP-AMP synthase (cGAS)
245.13 CHF - 980.54 CHF
Spezifikation
| Chemischer Name oder Material | 3-[1-(6,7-Dichloro-1 H-benzimidazol-2-yl)-5-hydroxy-3-methyl-1 H-pyrazol-4-yl]-1(3 H)-isobenzofuranone |
|---|---|
| CAS | 2262452-06-0 |
| Ziel | Synthase/Synthetase Inhibitors |
| Summenformel | C19H12Cl2N4O3 |
| Reinheit | 0.98 |
| Produktcode | Marke | Menge | Preis | Menge & Verfügbarkeit | |||||
|---|---|---|---|---|---|---|---|---|---|
| Produktcode | Marke | Menge | Preis | Menge & Verfügbarkeit | |||||
|
18736205
|
Tocris Bioscience™
7904/10 |
10 mg |
245.13 CHF
10 Milligramm |
Verfügbar ab: 11-07-2024
Loggen Sie sich ein, um den Lagerbestand zu sehen |
|||||
|
18766005
|
Tocris Bioscience™
7904/50 |
50 mg |
980.54 CHF
50 Milligramm |
Verfügbar ab: 11-07-2024
Loggen Sie sich ein, um den Lagerbestand zu sehen |
|||||
Beschreibung
RU.521 is a potent and selective cyclic GMP-AMP synthase (cGAS) inhibitor (Kd = 36.2 nM; IC50 values are 0.11 μM and 2.94 μM against m-cGAS and h-cGAS, respectively). RU.521 suppresses dsDNA-activated reporter activity but not 5'ppp-HP20 RNA or murine IFN-β-induced IFN-β1-dependent gene expression. RU.521 reduces constitutive expression of type I interferon in primary macrophages from a mouse model of Aicardi-Gouti?res syndrome. Pretreatment of chimeric antigen receptor (CAR) redirected T cells with RU.521 increases efficiency of virus-free gene editing by improving cell viability and CAR integration in cell line.Spezifikation
| 3-[1-(6,7-Dichloro-1 H-benzimidazol-2-yl)-5-hydroxy-3-methyl-1 H-pyrazol-4-yl]-1(3 H)-isobenzofuranone | |
| Synthase/Synthetase Inhibitors | |
| 0.98 |
| 2262452-06-0 | |
| C19H12Cl2N4O3 |